* Genzyme Corp., Cambridge, Mass., appointed Paul Hastings tothe newly created position of vice president of global marketing forits therapeutic division. And David Foster joined the company asdirector of government relations.* IMRE Corp., Seattle, appointed Martin Cleary as its CEO. Clearywas president, CEO and a director of Theragen, which merged withGenVec.* Microbiological Associates Inc., Rockville, Md., named JohnMcEntire as vice president, biotechnology group.* Somatix Therapy Corp., Alameda, Calif., named the company'spresident and CEO, David Carter, as chairman of the board.* BioChem Pharma Inc., Laval, Quebec, appointed Michael Grey aspresident of BioChem Therapeutic Inc., the company's whollyowned therapeutic subsidiary.* Matrix Pharmaceuticals Inc., Menlo Park, Calif., added RichardMurdock, H. Dubose Montgomery and J. Stephan Dolezaleck to itsboard of directors.* Arris Pharmaceutical Corp., South San Francisco, appointedRobert Stroud as senior staff fellow in structural biology.* Univax Biologics Inc., Rockville, Md., elected Joseph Cook Jr. toits board of directors.u LXR Biotechnology Inc., Richmond, Calif., named EugeneEidenberg as chairman, succeeding Mark Germain.* Cygnus Therapeutic Systems, Redwood City, Calif., promotedRoger Francis and Alan Russell to the positions of senior vicepresident, marketing and business development, and senior vicepresident, scientific affairs, respectively.* McKesson Corp., San Francisco, named David Mahoney presidentof its Healthcare Delivery Systems unit.* Organogenesis Inc., Canton, Mass., said Dale DeVore joined thecompany as managing director of its newly created BiomaterialsDivision.* Tanox Biosystems Inc., of Houston, promoted Eric Mirabel tovice president, intellectual property, and George Wang to vicepresident, process development and production.* CytoMed Inc., of Cambridge, Mass., appointed Peter Gund to itsscientific advisory board.* Orquest Inc., of Mountain View, Calif., appointed James Poser asvice president of research and development.* Human Genome Sciences Inc., of Rockville, Md., hired NancyBroadbent as senior vice president, chief financial officer anddirector, effective Oct. 24.* BioChem Pharma Inc., of Laval, Quebec, appointed GervaisDionne to the new position of executive vice president, research anddevelopment.

(c) 1997 American Health Consultants. All rights reserved.

No Comments